Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) — Q1 2022 Form 10-Q
Filing identity: The supplied filing is for Adagio Therapeutics, Inc., ticker ADGI, for the three months ended March 31, 2022. It is not filed under the name Invivyd; verify the issuer and reporting history before treating it as an Invivyd filing.
Business context and reporting period
Adagio was a clinical-stage biopharmaceutical company developing antibody-based products for infectious diseases. Its lead candidate, adintrevimab, was being studied for COVID-19 prevention and treatment. The unaudited quarter is compared with Q1 2021. The company had no product revenue and reported one operating segment.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $92.0 million | $34.0 million |
| Selling, general and administrative expense | $8.7 million | $3.7 million |
| Total operating expenses | $100.7 million | $38.7 million |
| Net loss | $100.7 million | $38.7 million |
| Net loss per share | $0.93 | Not applicable |
| Net cash used in operating activities | $59.0 million | $23.7 million |
| Cash and cash equivalents at period end | $532.2 million | $542.2 million at Dec. 31, 2021 |
| Total assets | $556.3 million | $620.1 million at Dec. 31, 2021 |
| Total liabilities | $96.9 million | $62.1 million at Dec. 31, 2021 |
There was no revenue from which to calculate margins. The company reported no debt balance in the presented balance sheet. Cash and cash equivalents plus current assets were $554.3 million; current liabilities were $95.5 million. The $10.0 million net decrease in cash included $49.0 million of proceeds from marketable-security maturities, which offset part of operating cash use.
R&D expense increased $58.0 million year over year, chiefly from higher adintrevimab manufacturing and clinical-trial costs, personnel costs, and discovery collaboration spending. SG&A rose $5.0 million, largely due to public-company and professional costs. The net loss increase was $62.0 million.
Material developments and outlook
- Enrollment in the EVADE prevention and STAMP treatment trials had been paused in January 2022 as Omicron spread. Management reported preliminary, statistically significant pre-Omicron efficacy across trial indications; results were preliminary and are not a substitute for final data.
- Adintrevimab had markedly reduced in-vitro neutralization activity against Omicron BA.2. Following FDA feedback in Q2 2022, the company paused its planned U.S. Emergency Use Authorization submission and said it would continue monitoring variants and consulting regulators. This makes potential authorization and commercial use uncertain.
- Management reported no study-drug-related adverse events or serious adverse events in the expanded Phase 1 higher-dose evaluation as of March 27, 2022.
- Management estimated cash would fund operations into the second half of 2024, based on its current operating plan and assumptions. The financial-statement note separately says existing cash was expected to cover operating expenses and capital expenditures for at least 12 months from issuance; these statements use different horizons and should be read in context.
- In April 2022, the company reduced contractually committed WuXi manufacturing volumes, decreasing prior minimum purchase obligations by $107.8 million and anticipating a future credit in the low eight figures. It also gave notice to terminate its TSRI research agreement.
- Former CEO and president Tillman Gerngross resigned in February 2022; forfeiture of his outstanding options produced a roughly $4.6 million reversal of SG&A stock-based compensation expense. The filing also describes leadership transitions and a search for a permanent CEO.
Principal risks include dependence on adintrevimab and changing viral variants, clinical and regulatory uncertainty, no revenue and continuing losses, reliance on WuXi as a sole-source manufacturer, possible trial and supply-chain disruption, and the need for additional capital over time. The company reported no material legal proceedings. It adopted the lease accounting standard ASC 842 on January 1, 2022, recording an operating lease right-of-use asset and liabilities without an impact on operating results or operating cash flows.
Most important facts for investors to verify
- Confirm the issuer identity, ticker, corporate name-change history, and whether this Adagio filing is relevant to the requested Invivyd entity.
- Check subsequent filings and regulatory updates for adintrevimab’s development status, variant susceptibility, trial follow-up, and any EUA or other authorization plans.
- Review final clinical-trial results and distinguish them from the preliminary pre-Omicron analyses described here.
- Validate the cash runway assumptions and reconcile the stated second-half-2024 estimate with the note’s minimum 12-month statement; assess actual cash burn and financing needs.
- Confirm the implementation and value of the April WuXi commitment reduction and credit, and assess remaining manufacturing exposure and the effect of terminating the TSRI agreement.